"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT01733186","Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects",,"Completed","Has Results","Degeneration Articular Cartilage Knee","Biological: CARTISTEM®","IKDC Score|VAS|Lysholm Score|KOOS Score","Medipost Co Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-0201-01","January 7, 2013","June 2, 2017","August 29, 2017","November 26, 2012","July 30, 2021","July 30, 2021","Cartilage Restoration Center; RUSH University Medical Center, Chicago, Illinois, United States|Cartilage Repair Center; Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01733186/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01733186"
2,"NCT01041001","Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury",,"Completed","No Results Available","Cartilage Injury|Osteoarthritis","Biological: Cartistem|Procedure: Microfracture treatment","ICRS Cartilage Repair Assessment will follow to determine the appropriate grade. The treatment will be considered efficacious if the ICRS grade drops by at least 1 grade or more from baseline to week 48.|Degree of improvement in the grade of joint pain measured on a 100-mm VAS (Visual Analogue Scale)|Grade of cartilage regeneration in patients who agreed to a biopsy during arthroscopy at week 48|Changes in WOMAC scores|Changes in IKDC Subjective Score|ICRS scores","Medipost Co Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-CRP-005","February 2009","December 2010","January 2011","December 30, 2009",,"April 20, 2017","Gachon University Gil Hospital, Incheon, Gyunggido, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Seoul Veterans Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01041001"
3,"NCT02755376","Development of Novel Strategy for Treatment of Anterior Cruciate Ligament (ACL) Injury Using Stem Cell",,"Completed","No Results Available","Deficiency of Anterior Cruciate Ligament","Biological: Cartistem(TM)|Biological: hyaluronic acid|Procedure: ACL reconstruction only","Bone formation on interface between bone tunnel and graft|Arthroscopic grading of graft|Telos stress X-ray|KT-2000|clinical knee scoring|Instability assessing with physical examination|Tunnel enlargement after anterior cruciate ligament reconstruction","Samsung Medical Center","All","20 Years to 50 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SMC 2013-07-117-002","January 1, 2014","April 28, 2016","December 1, 2018","April 28, 2016",,"April 10, 2019","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02755376"
4,"NCT04310215","Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus",,"Completed","No Results Available","Chondral or Osteochondral Lesion of Talus","Biological: CARTISTEM®|Procedure: Microfracture","ICRS-Cartilage Repair Assessment Total Score|ICRS-Cartilage Repair Assessment Overall Grade|Improvement degree of Cartilage Repair by MRI|Degree of Functional improvement in FAOS(Foot & Ankle Outcome Score)|Degree of Functional improvement in AOFAS(The American Orthopaedic Foot & Ankle Score)|Degree of Functional improvement in Tegner activity score|Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)|Degree of pain improvement in 100 mm VAS(Visual Analogue Scale)","Hyundai Bioland Co., Ltd.|Medipost Co Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CARTISTEM_2019_01","March 3, 2020","June 13, 2022","June 13, 2022","March 17, 2020",,"August 3, 2022","Kyunghee University Medical Center, Seoul, Dongdaemun-gu, Korea, Republic of|Gangnam Severance Hospital, Seoul, Gangnam-gu, Korea, Republic of|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of|Inha University Hospital, Incheon, Jung-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04310215"
5,"NCT01626677","Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect",,"Completed","No Results Available","Degenerative Osteoarthritis|Defect of Articular Cartilage","Biological: CARTISTEM|Procedure: Microfracture","Degree of improvement in knee assessments compared to the active control (microfracture)|Number of subjects with adverse events","Medipost Co Ltd.|Dong-A Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CARTISTEM_CR_F/U","June 2012","May 2015","May 2015","June 25, 2012",,"April 20, 2017","Inha University Hospital, Incheon, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Seoul Veterans Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01626677"
